Balancing efficacy and tolerability issues with statin therapy-considerations for the use of pitavastatin in special patient populations

US Endocrinology

Volumn 7, Issue 1, 2011, Pages 30-39

  Falko, James M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease (CVD); Chronic kidney disease (CKD); Co enzyme Q10; Coronary heart disease (CHD); Diabetes; Dyslipidemia; Elderly; High density lipoprotein cholesterol (HDL C); Hypercholesterolemia; Low density lipoprotein cholesterol (LDL C); Metabolic syndrome; Omega 3 fatty acid; Red yeast rice; Statin; Tolerability

Indexed keywords

EID: 84857213783     PISSN: 17583918     EISSN: 17583926     Source Type: Journal    
DOI: 10.17925/use.2011.07.01.30     Document Type: Article

References (144)

1. Roger VL, Go AS, Lloyd-Jones DM, et al., Heart Disease and Stroke Statistics-2011 Update: A Report From the American Heart Association, Circulation, 2011:123(4):e18-209.
2. Cardiovascular diseases (CVDs), Fact Sheet, 2009. Available at: www.who.int/mediacentre/factsheets/fs317/en/, (accessed December 29, 2010).
3. Heiss G, Tamir I, Davis CE, et al., Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study, Circulation, 1980;61:302-15.
4. Steiner G, How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD, Cardiovasc Drugs Ther, 2009;23:403-8
5. Assmann G, Dyslipidemia and global cardiovascular risk: clinical issues, Eur Heart J, 2006;(Suppl.)8:f40-6.
6. Sniderman A, Vu H, Cianflone K, Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels, Atherosclerosis, 1991;89:109-16
7. Lloyd-Jones DM, Larson MG, Beiser A, et al., Lifetime risk for developing coronary heart disease, Lancet, 1999;353:89-92.
8. Heron M, Hoyert DL, Murphy SL, et al., Deaths: final data for 2006, Natl Vital Stat Rep, 2009;57:1-134.
9. Alexander KP, Blazing MA, Rosenson RS, et al., Management of hyperlipidemia in older adults, J Cardiovasc Pharmacol Ther, 2009;14:49-58.
10. The next four decades. The older population in the United States: 2010 to 2050. Population estimates and projections, US Census Bureau, 2010. Available at: www.census.gov/prod/2010pubs/p25-1138.pdf (accessed 11 January 2011).
11. Houterman S, Verschuren WM, Hofman A, et al., Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study, J Intern Med, 1999;246:25-33.
12. Frost PH, Davis BR, Burlando AJ, et al., Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP), Circulation, 1996;94:2381-8.
13. Rubin SM, Sidney S, Black DM, et al., High blood cholesterol in elderly men and the excess risk for coronary heart disease, Ann Intern Med, 1990;113:916-20.
14. Benfante R, Reed D, Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?, JAMA, 1990;263:393-6
15. Castelli WP, Wilson PW, Levy D, et al., Cardiovascular risk factors in the elderly, Am J Cardiol, 1989;63:12-9H.
16. Assmann G, Cullen P, Schulte H, The Munster Heart Study (PROCAM). Results of follow-up at 8 years, Eur Heart J, 1998;19(Suppl. A):A2-11.
17. Kronmal RA, Cain KC, Ye Z, et al., Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data, Arch Intern Med, 1993;153:1065-73.
18. Shipley MJ, Pocock SJ, Marmot MG, Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study, BMJ, 1991;303:89-92
19. King H, Aubert RE, Herman WH, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care, 1998;21:1414-31
20. Boyle JP, Honeycutt AA, Narayan KM, et al., Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US, Diabetes Care, 2001;24:1936-40.
21. Anselmino M, Ryden L, Strategies to enhance cardiovascular disease prevention in patients with diabetes, Curr Opin Cardiol, 2009;24:461-7
22. Ryden L, Malmberg K, Reducing the impact of the diabetic heart's increased vulnerability to cardiovascular disease, Dialog Cardiovasc Med, 2000;5:5-22
23. Grundy SM, Cleeman JI, Merz CN, et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 2004;44:720-32.
24. Tuomilehto J, Rastenyte D, Epidemiology of microvascular disease and hypertension in diabetes, Chichester: Wiley, 1997
25. Stamler J, Vaccaro O, Neaton JD, et al., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 1993;16:434-44.
26. Mooradian AD, Dyslipidemia in type 2 diabetes mellitus, Nat Clin Pract Endocrinol Metab, 2009;5:150-9
27. Boden G, Laakso M, Lipids and glucose in type 2 diabetes: what is the cause and effect?, Diabetes Care, 2004;27:2253-9
28. Garvey WT, Kwon S, Zheng D, et al., Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance, Diabetes, 2003;52:453-62.
29. Ginsberg HN, Zhang YL, Hernandez-Ono A, Regulation of plasma triglycerides in insulin resistance and diabetes, Arch Med Res, 2005;36:232-40
30. Goldberg IJ, Clinical review 124: Diabetic dyslipidemia: causes and consequences, J Clin Endocrinol Metab, 2001;86:965-71
31. Krauss RM, Lipids and lipoproteins in patients with type 2 diabetes, Diabetes Care, 2004;27:1496-504
32. Despres JP, Lamarche B, Mauriege P, et al., Hyperinsulinemia as an independent risk factor for ischemic heart disease, N Engl J Med, 1996;334:952-7.
33. Reaven GM, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 1988;37:1595-607.
34. Austin MA, Edwards KL, Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes, Curr Opin Lipidol, 1996;7:167-71
35. Haffner SM, Mykkanen L, Festa A, et al., Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state, Circulation, 2000;101:975-80.
36. Attman PO, Samuelsson O, Alaupovic P, Lipoprotein metabolism and renal failure, Am J Kidney Dis, 1993;21:573-92
37. Samuelsson O, Aurell M, Knight-Gibson C, et al., Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency, Nephron, 1993;63:279-85.
38. Sahadevan M, Kasiske BL, Hyperlipidemia in kidney disease: causes and consequences, Curr Opin Nephrol Hypertens, 2002;11:323-9
39. Krolewski AS, Warram JH, Christlieb AR, Hypercholesterolemia-a determinant of renal function loss and deaths in IDDM patients with nephropathy, Kidney Int Suppl, 1994;45:S125-31
40. Manttari M, Tiula E, Alikoski T, et al., Effects of hypertension and dyslipidemia on the decline in renal function, Hypertension, 1995;26:670-5.
41. Hunsicker LG, Adler S, Caggiula A, et al., Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study, Kidney Int, 1997;51:1908-19.
42. Gall MA, Hougaard P, Borch-Johnsen K, et al., Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study, BMJ, 1997;314:783-8.
43. Attman PO, Alaupovic P, Samuelsson O, Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease, Kidney Int Suppl, 1999;71:S14-7
44. Buemi M, Senatore M, Corica F, et al., Statins and progressive renal disease, Med Res Rev, 2002;22:76-84.
45. Baigent C, Landray MJ, Reith C, et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 2011;377:2181-92.
46. Eckel RH, Alberti KG, Grundy SM, et al., The metabolic syndrome, Lancet, 2010;375:181-3.
47. Grundy SM, Obesity, metabolic syndrome, and cardiovascular disease, J Clin Endocrinol Metab, 2004;89:2595-600
48. Alexander CM, Landsman PB, Teutsch SM, et al., NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 2003;52:1210-4.
49. Pais R, Silaghi H, Silaghi AC, et al., Metabolic syndrome and risk for subsequent colorectal cancer, World J Gastroenterol, 2009;15:5141-8.
50. Lakka HM, Laaksonen DE, Lakka TA, et al., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 2002;288:2709-16.
51. Spratt KA, Managing diabetic dyslipidemia: aggressive approach, J Am Osteopath Assoc, 2009;109:S2-7
52. Franco OH, Massaro JM, Civil J, et al., Trajectories of entering the metabolic syndrome: the framingham heart study, Circulation, 2009;120:1943-50.
53. Grundy SM, Cleeman JI, Daniels SR, et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 2005;112:2735-52.
54. Toutouzas K, Drakopoulou M, Skoumas I, et al., Advancing therapy for hypercholesterolemia, Expert Opin Pharmacother, 2010;11:1659-72.
55. Corsini A, Bellosta S, Baetta R, et al., New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol Ther, 1999;84:413-28.
56. Cheung BM, Lauder IJ, Lau CP, et al., Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes, Br J Clin Pharmacol, 2004;57:640-51.
57. Grundy SM, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 1988;319:24-33
58. Bonetti PO, Lerman LO, Napoli C, et al., Statin effects beyond lipid lowering¬are they clinically relevant?, Eur Heart J, 2003;24:225-48.
59. Karnik NS, Maldonado JR, Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis, Psychosomatics, 2005;46:565-8
60. Hayashi T, Yokote K, Saito Y, et al., Pitavastatin: efficacy and safety in intensive lipid lowering, Expert Opin Pharmacother, 2007;8:2315-27.
61. Kapur NK, Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease, Expert Rev Cardiovasc Ther, 2007;5:161-75
62. Suzuki M, Iwasaki H, Fujikawa Y, et al., Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors, Bioorg Med Chem, 2001;9:2727-43.
63. Nakagawa S, Tanabe S, Tamaki T, et al., Effect of NK104, an HMG CoA reductase inhibitor on lipid metabolism in HepG2 cells, Jpn Pharmacol Ther, 2001;29:51-7.
64. Fujino H, Yamada I, Shimada S, et al., Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization, Xenobiotica, 2003;33:27-41.
65. Fujino H, Yamada I, Kojima J, et al., Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and humans, Xenobio Metabol Dispos, 1999;14:415-24.
66. Guengerich FP, Cytochrome p450 and chemical toxicology, Chem Res Toxicol, 2008;21:70-83
67. Kawashiri MA, Nohara A, Tada H, et al., Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study, Clin Pharmacol Ther, 2008;83:731-9.
68. Budinski DAV, Hounslow N, Gratsianski N, Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia, Clin Lipidol, 2009;4:291-302
69. Kowa, LIVALO [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc, 2010.
70. Ose L, Budinski D, Hounslow N, et al., Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia, Curr Med Res Opin, 2009;25:2755-64.
71. Ose L, Erratum, Curr Med Res Opin, 2010;26:1046
72. Gotto AM, Jr., Moon J, Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia, Expert Rev Cardiovasc Ther, 2010;8:1079-90.
73. Sasaki J, Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia, Vasc Health Risk Manag, 2010;6:997-1005
74. Noji Y, Higashikata T, Inazu A, et al., Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia, Atherosclerosis, 2002;163:157-64.
75. Ose L, Budinski D, Hounslow N, et al., Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia, Atherosclerosis, 2010;210:202-8.
76. Ose L, Budinski D, Hounslow N, et al., Erratum to 'Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia' (Atheroscler, 2010;202-208), Atheroscler, 2010;212:704.
77. Sasaki J, Ikeda Y, Kuribayashi T, et al., A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance, Clin Ther, 2008;30:1089-101.
78. Teramoto T, Saito Y, Yamada N, et al., Clinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia. Results of a multicenter long-term study, J Clin Therap Med, 2001;17:885-913.
79. Teramoto T, Shimano H, Yokote K, et al., Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia, J Atheroscler Thromb, 2009;16:654-61.
80. Kurihara Y, Douzono T, Kawakita K, et al., A large-scale, longterm, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet) - LIVALO Effectiveness and Safety (LIVES) Study, Jpn Pharmacol Ther, 2008;36:709-31.
81. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 1994;344:1383-9
82. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 2002;360:7-22
83. Shepherd J, Blauw GJ, Murphy MB, et al., Pravastatin in elderly individuals at risk for vascular disease (PROSPER): a randomised controlled trial, Lancet, 2002;360:1623-30.
84. Deedwania P, Stone PH, Bairey Merz CN, et al., Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE), Circulation, 2007;115:700-7.
85. Gotto AM, Jr., Statin therapy and the elderly: SAGE advice?, Circulation, 2007;115:681-3.
86. Jialal I, Amess W, Kaur M, Management of hypertriglyceridemia in the diabetic patient, Curr Diab Rep, 2010;10:316-20
87. Blasetto JW, Stein EA, Brown WV, et al., Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, Am J Cardiol, 2003;91:3-10C.
88. Collins R, Armitage J, Parish S, et al., MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 2003;361:2005-16.
89. Hitman GA, Colhoun H, Newman C, et al., Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS), Diabet Med, 2007;24:1313-21.
90. Betteridge DJ, Lipid lowering in diabetes mellitus, Curr Opin Lipidol, 2008;19:579-84
91. Keech A, Colquhoun D, Best J, et al., Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial, Diabetes Care, 2003;26:2713-21.
92. Baigent C, Keech A, Kearney PM, et al., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 2005;366:1267-78.
93. Goldberg RB, Guyton JR, Mazzone T, et al., Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study, Mayo Clin Proc, 2006;81:1579-88.
94. Steinmetz A, Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention, Diabetes Metab Res Rev, 2008;24:286-93
95. Tonkin AM, Chen L, Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Circulation, 2010;122:850-2
96. Buse JB, Bigger JT, Byington RP, et al., Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods, Am J Cardiol, 2007;99:21-33i.
97. Miller M, Managing mixed dyslipidemia in special populations, Prev Cardiol, 2010;13:78-83
98. Eldor R, Raz I, American Diabetes Association indications for statins in diabetes: is there evidence?, Diabetes Care, 2009;32(Suppl. 2):S384-91.
99. Brunzell JD, Davidson M, Furberg CD, et al., Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 2008;51:1512-24.
100. Deshmukh A, Mehta JL, Statins and renal disease: friend or foe?, Curr Atheroscler Rep, 2011;13:57-63
101. Wanner C, Krane V, Marz W, et al., Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics, Kidney Blood Press Res, 2004;27:259-66.
102. Wanner C, Krane V, Marz W, et al., Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 2005;353:238-48.
103. Nakamura H, Mizuno K, Ohashi Y, et al., Pravastatin and cardiovascular risk in moderate chronic kidney disease, Atherosclerosis, 2009;206:512-7.
104. Toba H, Mitani T, Takahashi T, et al., Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes, Clin Exp Pharmacol Physiol, 2010;37:1064-70.
105. Kimura K, Shimano H, Yokote K, et al., Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study, J Atheroscler Thromb, 2010;17:601-9.
106. Chapman MJ, Metabolic syndrome and type 2 diabetes: lipid and physiological consequences, Diab Vasc Dis Res, 2007;4(Suppl. 3):S5-8.
107. Brunzell JD, Davidson M, Furberg CD, et al., Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Diabetes Care, 2008;31:811-22.
108. Brown WV, Clark LT, Falko JM, et al., Optimal management of lipids in diabetes and metabolic syndrome, J Clin Lipidology, 2008;2:335-42.
109. Economic costs of diabetes in the U.S. In 2007, Diabetes Care, 2008;31:596-615.
110. Colhoun HM, Betteridge DJ, Durrington PN, et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 2004;364:685-96.
111. Goldberg RB, Mellies MJ, Sacks FM, et al., Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators, Circulation, 1998;98:2513-9.
112. Knopp RH, d'Emden M, Smilde JG, et al., Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in noninsulin-dependent diabetes mellitus (ASPEN), Diabetes Care, 2006;29:1478-85.
113. LaRosa JC, Grundy SM, Waters DD, et al., Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 2005;352:1425-35.
114. Ridker PM, Danielson E, Fonseca FA, et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 2008;359:2195-207.
115. Sever PS, Dahlof B, Poulter NR, et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial, Lancet, 2003;361:1149-58.
116. Stalenhoef AF, Ballantyne CM, Sarti C, et al., A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETABOLIC SYNDROME study, Eur Heart J, 2005;26:2664-72.
117. Kolluri R, Pinedo D, Edmonson-Holt A, et al., Dyslipidemia in South Asians living in a western community, J Clin Lipidology, 2009;3:14-8.
118. Rosengren A, Hawken S, Ounpuu S, et al., Association of psychosocial risk factors with risk for acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study, Lancet, 2004;364:953-62.
119. Joshi P, Islam S, Pais P, et al., Risk factors for early myocardial infarction in South Asians compared with individuals in other countries, JAMA, 2007;297:286-94.
120. Lee J, Heng D, Chia KS, et al., Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study, Int J Epidemiol, 2001;30:983-8.
121. Mohan V, Deepa R, Rani SS, et al., Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS No. 5), J Am Coll Cardiol, 2001;38:682-7.
122. Dhawan J, Bray CL, Warburton R, et al., Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?, Br Heart J, 1994;72:413-21.
123. Hughes LO, Wojciechowski AP, Raftery EB, Relationship between plasma cholesterol and coronary artery disease in Asians, Atherosclerosis, 1990;83:15-20
124. McKeigue PM, Miller GJ, Marmot MG, Coronary heart disease in south Asians overseas: a review, J Clin Epidemiol, 1989;42:597-609
125. Wild S, Roglic G, Green A, et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 2004;27:1047-53.
126. Armitage J, The safety of statins in clinical practice, Lancet, 2007;370:1781-90
127. Jones PH, Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering, Am J Cardiol, 2008;102:41L-7L
128. Robinson JG, Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges, Drugs Aging, 2009;26:917-31
129. Athyros VG, Tziomalos K, Karagiannis A, et al., Atorvastatin: safety and tolerability, Expert Opin Drug Saf, 2010;9:667-74.
130. Pedersen TR, Faergeman O, Kastelein JJ, et al., High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, JAMA, 2005;294:2437-45.
131. Jacobson TA, The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?, Mayo Clin Proc, 2006;81:1225-31
132. Gordon RY, Becker DJ, The Role of Red Yeast Rice for the Physician, Curr Atheroscler Rep, 2011;13:73-80
133. Caso G, Kelly P, McNurlan MA, et al., Effect of coenzyme q10 on myopathic symptoms in patients treated with statins, Am J Cardiol, 2007;99:1409-12.
134. Liu J, Zhang J, Shi Y, et al., Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials, Chin Med, 2006;1:4.
135. Franc S, Dejager S, Bruckert E, et al., A comprehensive description of muscle symptoms associated with lipid-lowering drugs, Cardiovasc Drugs Ther, 2003;17:459-65.
136. Thompson PD, Clarkson P, Karas RH, Statin-associated myopathy, JAMA, 2003;289:1681-90
137. Link E, Parish S, Armitage J, et al., SLCO1B1 variants and statin-induced myopathy-a genomewide study, N Engl J Med, 2008;359:789-99.
138. Ahmed W, Khan N, Glueck CJ, et al., Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients, Transl Res, 2009;153:11-6.
139. Eckel RH, Approach to the patient who is intolerant of statin therapy, J Clin Endocrinol Metab, 95:2015-22
140. Singh V, Deedwania P, Reducing morbidity and mortality in high risk patients with statins, Vasc Health Risk Manag, 2009;5:495-507
141. Walker DB, Jacobson TA, Initiating statins in the elderly: the evolving challenge, Curr Opin Endocrinol Diabetes Obes, 2008;15:182-7
142. Shimabukuro M, Higa M, Tanaka H, et al., Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus, Diabet Med, 2011; [Epub ahead of print].
143. Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients, Kowa Research Europe 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT00257686 (accessed March 9, 2010).
144. Ose L, Pitavastatin: a distinctive lipid-lowering drug, Clin Lipidol, 2010;5:309-23